Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE)

Anticancer Res. 2003 Nov-Dec;23(6D):5209-12.

Abstract

Background: Delayed chemotherapy-induced emesis (DCIE) has significant patient and health economic impact. Up to 50% of patients on chemotherapy may develop DCIE. There is no accepted standard of care for DCIE.

Patients and methods: A prospective observational study of patients with high grade DCIE needing admission to hospital over a 2-year period. Single cycle delayed anti-emetic failure (DAF) per patient is reported. Twenty-five mg/24 hours subcutaneous levomepromazine rescue (SLR) was used. Control of nausea and vomiting was recorded in 2 time-periods: 0 to 24 hours and 24 to 48 hours.

Results: Thirty-two patients (12 male, 20 female) required SLR. Median age 58 years (r. 35-76). Grade 0 nausea and vomiting (N and V) was attained within 24 hours in 75% and 81% of patients, respectively, and in 94% of patients for both by 48 hours. Side-effects of sedation and hypotension were mild.

Conclusion: Levomepromazine has efficacious anti-emetic qualities in the rescue of patients with high grade DCIE needing hospital admission.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antiemetics / administration & dosage*
  • Antiemetics / adverse effects
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Methotrimeprazine / administration & dosage*
  • Methotrimeprazine / adverse effects
  • Middle Aged
  • Nausea / drug therapy
  • Nausea / prevention & control
  • Neoplasms / drug therapy
  • Vomiting / chemically induced
  • Vomiting / drug therapy*
  • Vomiting / prevention & control

Substances

  • Antiemetics
  • Antineoplastic Agents
  • Methotrimeprazine